Механизмы формирования вариабельности артериального давления и возможности антигипертензивных препаратов в ее коррекции
https://doi.org/10.18087/cardio.2019.11.n803
Аннотация
Вариабельность артериального давления (ВАД) – это колебания артериального давления (АД) за определенный промежуток времени под воздействием различных факторов. Актуальность вопроса повышенной ВАД обусловлена предиктивной ценностью данного параметра как фактора риска развития фатальных и нефатальных сердечно-сосудистых, цереброваскулярных и почечных осложнений. Доказано, что в возникновении повышенной ВАД ведущую роль играют нарушения в функционировании барорефлекторного аппарата магистральных артерий, которые, в свою очередь, опосредованы повышением жесткости сосудистого русла, эффектами ангиотензина II и симпатической части вегетативной нервной системы, дисфункцией эндотелия, дефицитом оксида азота и процессами старения в том числе сосудистого. Преимущества в коррекции повышенной ВАД имеют антигипертензивные препараты, воздействующие на максимальное количество патофизиологических звеньев ее повышения. Такими препаратами являются периндоприл и амлодипин, которые способны влиять практически на весь спектр причин возникновения повышенной ВАД и оптимальным образом снижать риск развития сердечно-сосудистых осложнений.
Об авторах
А. И. КочетковРоссия
Москва
SPIN 9212-6010
О. Д. Остроумова
Россия
Москва
Е. В. Борисова
Россия
Москва
Г. Ф. Пиксина
Россия
Москва
Список литературы
1. Parati G, Ochoa JE, Salvi P, Schillaci G. Arterial Stiffness and Blood Pressure Variability. Elsevier, 2015. P.117128. ISBN: 9780128013878. DOI: 10.1016/B9780128013878.000120. In: Early Vascular Aging (EVA) Elsevier;
2. Parati G, Stergiou GS, Dolan E, Bilo G. Blood pressure variability: clinical relevance and application. The Journal of Clinical Hypertension. 2018;20(7):1133–7. DOI: 10.1111/jch.13304
3. Mancia G, Grassi G. Mechanisms and Clinical Implications of Blood Pressure Variability: Journal of Cardiovascular Pharmacology. 2000;35 (7 Suppl 4):S15–9. DOI: 10.1097/0000534420000000400003
4. Остроумова О.Д., Борисова Е.В., Павлеева Е.Е. Вариабельность артериального давления. Межвизитная вариабельность артериального давления. Кардиология. 2017;57(11):6875. DOI: 10.18087/cardio.2017.11.10056
5. Остроумова О.Д., Кочетков А.И., Гусева Т.Ф. Вариабельность артериального давления при артериальной гипертензии в сочетании с ишемической болезнью сердца: прогностическая значимость и возможности коррекции в реальной клинической практике. Артериальная гипертензия. 2018;24(2):24656. DOI: 10.18705/1607419X2018242246256
6. Conway J. Hemodynamic aspects of hypertension. Labile hypertension: the problem. Circulation Research. 1970;27(1 Suppl 1):43–7. PMID: 5423301
7. Watson RD, Stallard TJ, Flinn RM, Littler WA. Factors determining direct arterial pressure and its variability in hypertensive man. Hypertension. 1980;2(3):333–41. DOI: 10.1161/01.HYP.2.3.333
8. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24Hour Blood Pressure Mean and Variability to Severity of TargetOrgan Damage in Hypertension: Journal of Hypertension. 1987;5(1):93–8. DOI: 10.1097/0000487219870200000013
9. Frattola A, Parati G, Cuspidi C, Albini F, Mancia G. Prognostic value of 24hour blood pressure variability. Journal of Hypertension. 1993;11(10):1133–7. DOI: 10.1097/0000487219931000000019
10. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B et al. Prognostic significance of visittovisit variability, maximum systolic blood pressure, and episodic hypertension. The Lancet. 2010;375(9718):895–905. DOI: 10.1016/S01406736(10)60308X
11. Rothwell PM, Howard SC, Dolan E, O’Brien E, Dobson JE, Dahlöf B et al. Effects of β blockers and calciumchannel blockers on withinindividual variability in blood pressure and risk of stroke. The Lancet Neurology. 2010;9(5):469–80. DOI: 10.1016/S14744422(10)700661
12. Stevens SL, Wood S, Koshiaris C, Law K, Glasziou P, Stevens RJ et al. Blood pressure variability and cardiovascular disease: systematic review and metaanalysis. BMJ. 2016;354:i4098. DOI: 10.1136/bmj.i4098
13. Mena LJ, Felix VG, Melgarejo JD, Maestre GE. 24-Hour Blood Pressure Variability Assessed by Average Real Variability: A Systematic Review and Meta-Analysis. Journal of the American Heart Association. 2017;6(10):e006895. DOI: 10.1161/JAHA.117.006895
14. VidalPetiot E, Stebbins A, Chiswell K, Ardissino D, Aylward PE, Cannon CP et al. Visittovisit variability of blood pressure and cardiovascular outcomes in patients with stable coronary heart disease. Insights from the STABILITY trial. European Heart Journal. 2017;38(37):2813–22. DOI: 10.1093/eurheartj/ehx250
15. Gosmanova EO, Mikkelsen MK, Molnar MZ, Lu JL, Yessayan LT, KalantarZadeh K et al. Association of Systolic Blood Pressure Variability With Mortality, Coronary Heart Disease, Stroke, and Renal Disease. Journal of the American College of Cardiology. 2016;68(13):1375–86. DOI: 10.1016/j.jacc.2016.06.054
16. Остроумова О.Д., Борисова Е.В., Остроумова Т.М., Кочетков А.И. Вариабельность артериального давления в течение суток: прогностическое значение, методы оценки и влияние антигипертензивной терапии. Кардиология. 2017;57(12):6272. DOI: 10.18087/cardio.2017.12.10068
17. Tatasciore A, Renda G, Zimarino M, Soccio M, Bilo G, Parati G et al. Awake Systolic Blood Pressure Variability Correlates With TargetOrgan Damage in Hypertensive Subjects. Hypertension. 2007;50(2):325–32. DOI: 10.1161/HYPERTENSIONAHA.107.090084
18. Ozawa M, Tamura K, Okano Y, Matsushita K, Ikeya Y, Masuda S et al. Blood Pressure Variability As Well As Blood Pressure Level is Important for Left Ventricular Hypertrophy and BrachialAnkle Pulse Wave Velocity in Hypertensives. Clinical and Experimental Hypertension. 2009;31(8):669–79. DOI: 10.3109/10641960903407033
19. Кастанаян А.А., Железняк Е.И., Хагуш А.К., Демидова А.А., Карташова Е.А., Жулитов А.Ю. Взаимосвязь вариабельности артериального давления и сердечнососудистого ремоделирования при развитии артериальной гипертензии в пожилом возрасте. Артериальная гипертензия 2016;22(4):389400. DOI: 10.18705/1607419X2016224389400
20. Juhanoja EP, Niiranen TJ, Johansson JK, Puukka PJ, Jula AM. Agreement between ambulatory, home, and office blood pressure variability. Journal of Hypertension. 2016;34(1):61–7. DOI: 10.1097/HJH.0000000000000772
21. Madden JM, O’Flynn AM, Fitzgerald AP, Kearney PM. Correlation between shortterm blood pressure variability and leftventricular mass index: a metaanalysis. Hypertension Research. 2016;39(3):171–7. DOI: 10.1038/hr.2015.126
22. Kawai T, Ohishi M, Kamide K, Nakama C, Onishi M, Ito N et al. Differences between daytime and nighttime blood pressure variability regarding systemic atherosclerotic change and renal function. Hypertension Research. 2013;36(3):232–9. DOI: 10.1038/hr.2012.162
23. Ichihara A, Kaneshiro Y, Takemitsu T, Sakoda M, Hayashi M. Ambulatory blood pressure variability and brachial–ankle pulse wave velocity in untreated hypertensive patients. Journal of Human Hypertension. 2006;20(7):529–36. DOI: 10.1038/sj.jhh.1002023
24. Schillaci G, Bilo G, Pucci G, Laurent S, MacquinMavier I, Boutouyrie P et al. Relationship Between ShortTerm Blood Pressure Variability and LargeArtery Stiffness in Human Hypertension: Findings From 2 Large Databases. Hypertension. 2012;60(2):369–77. DOI: 10.1161/HYPERTENSIONAHA.112.197491
25. Eguchi K, Hoshide S, Schwartz JE, Shimada K, Kario K. VisittoVisit and Ambulatory Blood Pressure Variability as Predictors of Incident Cardiovascular Events in Patients With Hypertension. American Journal of Hypertension. 2012;25(9):962–8. DOI: 10.1038/ajh.2012.75
26. Pringle E, Phillips C, Thijs L, Davidson C, Staessen JA, de Leeuw PW et al. Systolic blood pressure variability as a risk factor for stroke and cardiovascular mortality in the elderly hypertensive population: Journal of Hypertension. 2003;21(12):2251–7. DOI: 10.1097/0000487220031200000012
27. Verdecchia P, Angeli F, Gattobigio R, Rapicetta C, Reboldi G. Impact of Blood Pressure Variability on Cardiac and Cerebrovascular Complications in Hypertension. American Journal of Hypertension. 2007;20(2):154–61. DOI: 10.1016/j.amjhyper.2006.07.017
28. Mena LJ, Maestre GE, Hansen TW, Thijs L, Liu Y, Boggia J et al. How Many Measurements Are Needed to Estimate Blood Pressure Variability Without Loss of Prognostic Information? American Journal of Hypertension. 2014;27(1):46–55. DOI: 10.1093/ajh/hpt142
29. Васюк Ю.А., Иванова С.В., Школьник Е.Л., Котовская Ю.В., Милягин В.А., Олейников В.Э. и др. Согласованное мнение российских экспертов по оценке артериальной жесткости в клинической практике. Кардиоваскулярная терапия и профилактика. 2016;15(2):419. DOI: 10.15829/1728880020162419
30. Grassi G, Turri C, Vailati S, Dell’Oro R, Mancia G. Muscle and Skin Sympathetic Nerve Traffic During the “WhiteCoat” Effect. Circulation. 1999;100(3):222–5. DOI: 10.1161/01.CIR.100.3.222
31. Mancia G, Parati G, Pomidossi G, Casadei R, Di Rienzo M, Zanchetti A. Arterial baroreflexes and blood pressure and heart rate variabilities in humans. Hypertension. 1986;8(2):147–53. DOI: 10.1161/01.HYP.8.2.147
32. Heusser K, Tank J, Engeli S, Diedrich A, Menne J, Eckert S et al. Carotid Baroreceptor Stimulation, Sympathetic Activity, Baroreflex Function, and Blood Pressure in Hypertensive Patients. Hypertension. 2010;55(3):619–26. DOI: 10.1161/HYPERTENSIONAHA.109.140665
33. Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. The Role of Renin–Angiotensin–Aldosterone System and Its New Components in Arterial Stiffness and Vascular Aging. High Blood Pressure & Cardiovascular Prevention. 2018;25(2):137–45. DOI: 10.1007/s4029201802525
34. Avolio AP, Ke Xu, Butlin M. Effect of large arteries on blood pressure variability. 2013 35th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). Osaka: IEEE, 2013. P.40784081. DOI: 10.1109/EMBC.2013.6610441.
35. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensivedrug class on interindividual variation in blood pressure and risk of stroke: a systematic review and metaanalysis. The Lancet. 2010;375(9718):906–15. DOI: 10.1016/S01406736(10)602358
36. Webb AJS, Rothwell PM. Effect of Dose and Combination of Antihypertensives on Interindividual Blood Pressure Variability: A Systematic Review. Stroke. 2011;42(10):2860–5. DOI: 10.1161/STROKEAHA.110.611566
37. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. European Heart Journal. 2018;39(33):3021–104. DOI: 10.1093/eurheartj/ehy339
38. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D et al. Treatment of Hypertension in Patients 80 Years of Age or Older. New England Journal of Medicine. 2008;358(18):1887–98. DOI: 10.1056/NEJMoa0801369
39. PROGRESS Collaborative Group. Randomised trial of a perindoprilbased bloodpressurelowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. The Lancet. 2001;358(9287):1033–41. DOI: 10.1016/S01406736(01)061785
40. Patel A. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. The Lancet. 2007;370(9590):829–40. DOI: 10.1016/S01406736(07)613038
41. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, doubleblind, placebocontrolled, multicentre trial (the EUROPA study). Lancet (London, England). 2003;362(9386):782–8. DOI: 10.1016/s01406736(03)142869
42. RodriguezGranillo GA, Vos J, Bruining N, GarciaGarcia HM, de Winter S, Ligthart JMR et al. LongTerm Effect of Perindopril on Coronary Atherosclerosis Progression (from the PERindopril’s Prospective Effect on Coronary aTherosclerosis by Angiography and IntraVascular Ultrasound Evaluation [PERSPECTIVE] Study). The American Journal of Cardiology. 2007;100(2):159–63. DOI: 10.1016/j.amjcard.2007.02.073
43. Bots ML, Remme WJ, Lüscher TF, Fox KM, Bertrand M, Ferrari R et al. ACE Inhibition and Endothelial Function: Main Findings of PERFECT, a SubStudy of the EUROPA Trial. Cardiovascular Drugs and Therapy. 2007;21(4):269–79. DOI: 10.1007/s1055700760413
44. Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML. The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. European Heart Journal. 2005;26(14):1369–78. DOI: 10.1093/eurheartj/ehi225
45. Scientific Committee of the PERTINENT SubStudy, EUROPAPERTINENT Investigators. PERTINENT – perindoprilthrombosis, inflammation, endothelial dysfunction and neurohormonal activation trial: a substudy of the EUROPA study. Cardiovascular Drugs and Therapy. 2003;17(1):83–91. PMID: 12843690
46. Недогода С.В., Чумачек Е.В., Ледяева А.А., Цома В.В., Саласюк А.С., Смирнова В.О. и др. Оптимизация контроля артериального давления, органопротекции и метаболических нарушений с помощью фиксированной комбинации периндоприла и индапамида у пациентов с артериальной гипертензией. Кардиология 2017;57(2):511. DOI: 10.18565/cardio.2017.2.511
47. Koz C, Baysan O, Yokusoglu M, Uzun M, Yildirim M, Hasimi A et al. The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2009;15(7):PI4145. PMID: 19564839
48. Sesso HD. CReactive Protein and the Risk of Developing Hypertension. JAMA. 2003;290(22):2945–51. DOI: 10.1001/jama.290.22.2945
49. Blake GJ, Rifai N, Buring JE, Ridker PM. Blood Pressure, CReactive Protein, and Risk of Future Cardiovascular Events. Circulation. 2003;108(24):2993–9. DOI: 10.1161/01.CIR.0000104566.10178.AF
50. Rocha R, Rudolph AE, Frierdich GE, Nachowiak DA, Kekec BK, Blomme EAG et al. Aldosterone induces a vascular inflammatory phenotype in the rat heart. American Journal of PhysiologyHeart and Circulatory Physiology. 2002;283(5):H1802–10. DOI: 10.1152/ajpheart.01096.2001
51. Rocha R, MartinBerger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective Aldosterone Blockade Prevents Angiotensin II/SaltInduced Vascular Inflammation in the Rat Heart. Endocrinology. 2002;143(12):4828–36. DOI: 10.1210/en.2002220120
52. FernandezReal JM, Vayreda M, Richart C, Gutierrez C, Broch M, Vendrell J et al. Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. The Journal of Clinical Endocrinology and Metabolism. 2001;86(3):1154–9. DOI: 10.1210/jcem.86.3.7305
53. Park S, Lakatta EG. Role of Inflammation in the Pathogenesis of Arterial Stiffness. Yonsei Medical Journal. 2012;53(2):258–61. DOI: 10.3349/ymj.2012.53.2.258
54. Malik EZ, Abdulhadi B, Mezue KN, Lerma EV, Rangaswami J. Clinical hypertension: Blood pressure variability. DiseaseaMonth. 2018;64(1):5–13. DOI: 10.1016/j.disamonth.2017.08.003
55. Wang M, Zhang J, Jiang LQ, Spinetti G, Pintus G, Monticone R et al. Proinflammatory Profile Within the Grossly Normal Aged Human Aortic Wall. Hypertension. 2007;50(1):219–27. DOI: 10.1161/HYPERTENSIONAHA.107.089409
56. Kukes V.G. Clinical pharmacology: Textbook. 3rd edition, revised and enlarged.M.: GEOTARMedia; 944 p.
57. Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nature Reviews Immunology. 2011;11(2):85–97. DOI: 10.1038/nri2921
58. Ceconi C, Francolini G, Bastianon D, Gitti GL, Comini L, Ferrari R. Differences in the Effect of Angiotensinconverting Enzyme Inhibitors on the Rate of Endothelial Cell Apoptosis: In Vitro and In Vivo Studies. Cardiovascular Drugs and Therapy. 2007;21(6):423–9. DOI: 10.1007/s1055700760685
59. Ferrari R. Treatment with angiotensinconverting enzyme inhibitors: insight into perindopril cardiovascular protection. European Heart Journal Supplements. 2008;10(Suppl G):G13–20. DOI: 10.1093/eurheartj/sun025
60. Partovian C, Benetos A, Pommiès JP, Mischler W, Safar ME. Effects of a chronic highsalt diet on large artery structure: role of endogenous bradykinin. American Journal of PhysiologyHeart and Circulatory Physiology. 1998;274(5):H1423–8. DOI: 10.1152/ajpheart.1998.274.5.H1423
61. Safar M. Factors influencing arterial stiffness in systolic hypertension in the elderly: role of sodium and the reninangiotensin system. American Journal of Hypertension. 2003;16(3):249–58. DOI: 10.1016/S08957061(02)032594
62. Esler M. Looking at the sympathetic nervous system as a primary source. In: Hypertension in the twentieth century: concepts and achievements. Birkenhäger WH, Robertson JIS, Zanchetti A, Reid JL, editors Amsterdam: Elsevier; 580 p. [P. 81103]. ISBN 9780444514509
63. Остроумова О.Д., Викентьев В.В., Абросимов А.Г., Смолярчук Е.А. Дигидропиридиновые антагонисты кальция: осознанный выбор. Системные гипертензии. 2017;14(1):618
64. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D et al. Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure: The CAMELOT Study: A Randomized Controlled Trial. JAMA. 2004;292(18):2217–25. DOI: 10.1001/jama.292.18.2217
65. Brener SJ, Ivanc TB, Poliszczuk R, Chen M, Tuzcu EM, Hu T et al. Antihypertensive therapy and regression of coronary artery disease: Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurrences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. American Heart Journal. 2006;152(6):1059–63. DOI: 10.1016/j.ahj.2006.07.022
66. Pitt B, Byington RP, Furberg CD, Hunninghake DB, Mancini GBJ, Miller ME et al. Effect of Amlodipine on the Progression of Atherosclerosis and the Occurrence of Clinical Events. Circulation. 2000;102(13):1503–10. DOI: 10.1161/01.CIR.102.13.1503
67. Загидуллин Н.Ш., Зулкарнеев Р.Х., Щербакова Е.С., Сафина Ю.Ф., Загидуллин Ш.З. Артериальная жесткость как маркер риска сердечнососудистых событий и возможности ее снижения при современной антигипертензивной терапии. Казанский медицинский журнал. 2014;95(4):57581
68. Dudenbostel T, Glasser SP. Effects of Antihypertensive Drugs on Arterial Stiffness. Cardiology in Review. 2012;20(5):259–63. DOI: 10.1097/CRD.0b013e31825d0a44
69. Mason RP, Walter MF, Trumbore MW, Olmstead Jr EG, Mason PE. Membrane Antioxidant Effects of the Charged Dihydropyridine Calcium Antagonist Amlodipine. Journal of Molecular and Cellular Cardiology. 1999;31(1):275–81. DOI: 10.1006/jmcc.1998.0867
70. Takami T, Shigemasa M. Efficacy of Various Antihypertensive Agents as Evaluated by Indices of Vascular Stiffness in Elderly Hypertensive Patients. Hypertension Research. 2003;26(8):609–14. DOI: 10.1291/hypres.26.609
Рецензия
Для цитирования:
Кочетков А.И., Остроумова О.Д., Борисова Е.В., Пиксина Г.Ф. Механизмы формирования вариабельности артериального давления и возможности антигипертензивных препаратов в ее коррекции. Кардиология. 2019;59(11):56-65. https://doi.org/10.18087/cardio.2019.11.n803
For citation:
Kochetkov A.I., Ostroumova O.D., Borisova E.V., Piksina G.F. Mechanisms for the Development of Blood Pressure Variability and the Potential of Antihypertensive Drugs in Their Correction. Kardiologiia. 2019;59(11):56-65. (In Russ.) https://doi.org/10.18087/cardio.2019.11.n803